Searchable abstracts of presentations at key conferences in endocrinology

ea0029p483 | Developmental endocrinology | ICEECE2012

GH replacement therapy in patients with primary paediatric brain tumours

Seregni E. , Pallotti F. , Biassoni V. , Catania S. , Gandola L. , Spreafico F. , Terenziani M. , Mallia A. , Bombardieri E. , Massimino M.

Aim: Endocrinopathies are frequent complications in paediatric patients with primary brain tumours (PBT) and among them GH deficiency (GHD) is of particular relevance. In this study we evaluated the incidence of GHD and the impact of GH therapy in a large series of PBT bearing patients or adult patients previously treated for PBT.Methods: From January 2001 to December 2011 more than 700 PBT patients were screened for endocrine complications. GHD was expl...

ea0083rdp3 | Reproductive and Developmental Endocrinology | EYES2022

Pharmacodynamics and safety of human recombinant luteinising hormone (LH) in hypogonadotropic hypogonadal men: a new ongoing multicenter study

F. Costantino , G. Spaggiari , L. Dalla valentina , C de Angelis , E Ferrante , C. Furini , F Garifalos , R. Indirli , F Lombardo , G. Mantovani , D Menafra , M Notarianni , F Pallotti , R Pivonello , M. Romeo , M. Simoni , D. Santi

State of the art: In pharmacology, human chorionic gonadotropin (hCG) is considered equivalent to luteinising hormone (LH) since both act on the same receptor. Thus, when testicular function needs to be clinically restored (i.e. in case of hypogonadotropic hypogonadism [HH]), hCG is used instead of LH. However, growing evidences showed LH and hCG activate different molecular pathways and offer different outcomes in women undergoing assisted reproduction. The different action b...